Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1358894 (Double-blind, Randomised, Placebo-controlled, Parallel-group Design) and Evaluation of Midazolam Interaction (Nested, Open, Fixed-sequence, Intra-individual Comparison) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs BI 1358894 (Primary) ; Midazolam
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Jul 2019 Status changed from active, no longer recruiting to completed.
- 25 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2019 Planned End Date changed from 3 Jul 2019 to 15 Jul 2019.